Moreover, anti-HSPG drugs such as necuparanib have been reported to lead to MMP1 activity restriction and tissue inhibitor of metalloproteinase 3 (TIMP3) increase in PC patients [129, 130, 300–302]. This evidence concerns the gene TIMP3 and pachyonychia congenita.